Q0167 HCPCS code: Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

Q0167 is the HCPCS Level II code for dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen. In 2023 Medicare paid an average of $0.53 per service for Q0167 across 1,104 services. Its Medicare coverage code is D (Special coverage instructions apply): Medicare covers it when its national or local coverage criteria are met. The NCCI unit limit is 108 per day on DME suppliers. Medicare volume fell 48% from 2022 to 2023 (2,130 to 1,104 services). In 2023, 12 suppliers billed Medicare for Q0167 (purchases), serving 15 beneficiaries.

Code details

Who bills Q0167 (2023)

Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.

Medicare utilization for Q0167, 2022–2023

NCCI unit limits (MUE)

Medicare policy articles for this code

• A52480: Oral Antiemetic Drugs (Replacement for Intravenous Antiemetics) - Policy Article (CGS Administrators, LLC (DME MAC) Noridian Healthcare Solutions, LLC (DME MAC)) — mentions this code in its coding guidance

Covered diagnoses (1,280 ICD-10-CM codes)

The diagnoses most often listed as covered in the policy articles above:

Showing 10 of 1,280. The full list, non-covered diagnoses and CSV export are in Caduvo.

What changed for Q0167

• 1998-04-01: Q0167 added to HCPCS Level II
• Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01

Frequently asked questions

What is HCPCS code Q0167?

Q0167 is the HCPCS Level II code for dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen. Short descriptor: "Dronabinol 2.5mg oral".

How much does Medicare pay for Q0167?

In 2023, the average Medicare payment was $0.53 per service (average allowed $0.72).

Does Medicare cover Q0167?

Coverage code D — Special coverage instructions apply. Medicare covers it when its national or local coverage criteria are met.

Which diagnoses support coverage for Q0167?

Medicare policy articles that cite Q0167 list 1,280 covered ICD-10-CM diagnosis codes across 1 article. The most cited include C00.0 (Malignant neoplasm of external upper lip), C00.1 (Malignant neoplasm of external lower lip), C00.3 (Malignant neoplasm of upper lip, inner aspect). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.

How many units of Q0167 can be billed per day?

108 on DME suppliers; 108 on outpatient hospital claims (NCCI medically unlikely edits).

Related Q01 codes

• Q0111 — Wet mounts, including preparations of vaginal, cervical or skin specimens
• Q0112 — All potassium hydroxide (koh) preparations
• Q0113 — Pinworm examinations
• Q0114 — Fern test
• Q0115 — Post-coital direct, qualitative examinations of vaginal or cervical mucous
• Q0138 — Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
• Q0139 — Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)
• Q0144 — Azithromycin dihydrate, oral, capsules/powder, 1 gram
• Q0155 — Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
• Q0161 — Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
• Q0162 — Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
• Q0163 — Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen

Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.

Next steps

• Run a reimbursement report for a device billed under Q0167
• Watch Q0167 for fee, coverage and descriptor changes
• Build a full Medicare revenue model for Q0167

Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.

All Q codes · HCPCS lookup